New Parkinson's drug candidate takes first step in human safety trial
NCT ID NCT06088784
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This early-stage study tested a new oral drug, ATH-399A, in 76 healthy adults to see if it is safe and how the body processes it. The goal is to gather information needed to develop a treatment for Parkinson's disease. Participants took single or multiple doses, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Syneos Quebec Canada
Québec, QC G1P 0A2, Canada
Conditions
Explore the condition pages connected to this study.